15851
document
Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators . OBJECTIVES This study evaluated the effects of azimilide dihydrochloride ( AZ ) on anti-tachycardia pacing ( ATP ) and shock-terminated events in patients with implantable cardioverter defibrillators ( ICDs ) . BACKGROUND Animal studies have shown the effectiveness of AZ for therapy of supraventricular and ventricular tachycardia ( VT ) . Azimilide dihydrochloride was investigated as adjunctive treatment for reducing the frequency of VT and , thus , the need for ICD therapies , including ATP and cardioversion/defibrillation ( ICD shocks ) in patients with inducible monomorphic VT. METHODS A total of 172 patients were randomized to daily treatment with placebo , 35 mg , 75 mg , or 125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs . The majority of patients had a history of documented remote myocardial infarction and congestive heart failure New York Heart Association class II or III . RESULTS The frequency of appropriate shocks and ATP were significantly decreased among AZ-treated patients compared with placebo patients . The incidence of ICD therapies per patient-year among the placebo group was 36 , and it was 10 , 12 , and 9 among 35 mg , 75 mg , and 125 mg AZ patients , respectively ( hazard ratio = 0.31 , p = 0.0001 ) . Azimilide dihydrochloride was generally well tolerated and did not affect left ventricular ejection fraction or minimal energy requirements for defibrillation or pacing . CONCLUSIONS Azimilide dihydrochloride may be a safe and effective drug for reducing the frequency of VT and ventricular fibrillation in patients with implanted ICDs .
15852
Intervention_Pharmacological
Azimilide
15853
Intervention_Pharmacological
azimilide dihydrochloride ( AZ )
15854
Intervention_Pharmacological
Azimilide dihydrochloride
15855
Intervention_Control
placebo
15856
Intervention_Pharmacological
oral AZ
15857
Intervention_Pharmacological
Azimilide dihydrochloride
15858
Outcome_Physical
recurrent ventricular tachyarrhythmias
15859
Outcome_Physical
anti-tachycardia pacing ( ATP )
15860
Outcome_Physical
shock-terminated events
15861
Outcome_Physical
frequency of appropriate shocks and ATP
15862
Outcome_Other
incidence of ICD therapies per patient-year
15863
Outcome_Other
well tolerated
15864
Outcome_Physical
affect left ventricular ejection fraction or
15865
Outcome_Other
minimal energy requirements for defibrillation or pacing
15866
Outcome_Physical
.
15867
Outcome_Physical
frequency of VT and ventricular fibrillation
15868
Participant_Condition
implantable cardioverter defibrillators
15869
Participant_Condition
implantable cardioverter defibrillators
15870
Participant_Sample-size
172
15871
Participant_Condition
ICDs
15872
Participant_Condition
remote myocardial infarction and congestive heart failure